High-Dose Intravenous Immunoglobulin Treatment in Two Patients With Acquired Factor V Inhibitors

American Journal of Hematology

Volumn 74, Issue 3, 2003, Pages 187-190

  De Raucourt, Emmanuelle ^a   Barbier, Christophe ^a   Sinda, Patrick ^a   Dib, Mamoun ^b   Peltier, Jean Yves ^a   Ternisien, Catherine ^b  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Acquired factor V inhibitor; Intravenous immunoglobulin treatment

Indexed keywords

IMMUNOGLOBULIN; THROMBIN;

ACQUIRED FACTOR V INHIBITOR; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME;

ADULT; BLOOD COAGULATION TESTS; BLOOD COMPONENT TRANSFUSION; FACTOR V; FACTOR V DEFICIENCY; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0242266991     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10420     Document Type: Article

References (10)

1. Streiff MB, Ness M. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002;42:18-26.
2. Knobl P, Lechner K. Acquired factor V deficiency inhibitors. Bailliere's Clin Haematol 1998;11:305-318.
3. Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 2002;99:3985-3992
4. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:869-872.
5. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88-96.
6. Ortel TL, Moore KD, Quinn-Allen MA, et al. Inhibitory antifactor V antibodies bind to factor V C2 domain and are associated with hemorrhagic manifestations. Blood 1998;91:4188-4196.
7. Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997;19:226-231.
8. Spero JA. Bovine thrombin-induced inhibitor of FV and bleeding risks in postoperative neurosurgical patients. J Neurosurg 1993;78:817-820.
9. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228.
10. Bayani N, Rugina M, Haddad-Vergnes L, Lelong F. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 2002;71:33-36.